Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fusion protein therapeutics - Altor BioScience

Drug Profile

Research programme: fusion protein therapeutics - Altor BioScience

Alternative Names: 264scTCR/IgG1; ALT-802; ALT-804; Antiviral TCR - Ab; Antiviral TCR - Ck; IMPACT™ fusion proteins research programme - Altor BioScience; N-820; STAR-based therapeutics research programme - Altor BioScience; STAR-IMPACT; T cell receptor IgG1 fusion protein; T cell receptor IL-2 fusion protein

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altor BioScience Corporation; Massachusetts General Hospital
  • Class Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Interleukin 15 receptor antagonists; Interleukin-15 receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Burkitt's lymphoma
  • No development reported Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Viral infections

Most Recent Events

  • 01 Dec 2018 Preclinical trials in Burkitt's lymphoma in USA (unspecified route)
  • 01 Dec 2018 Pharmacodynamics data from a preclinical trial in Burkitt's lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top